Ocular Therapeutix (OCUL) News Today

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

$5.22

-0.64 (-10.92%)

(As of 04/19/2024 ET)

Source

Source	Headline
	Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Ocular Therapeutix (OCUL) markets.businessinsider.com - April 19 at 12:40 PM
	Ocular Therapeutix (NASDAQ:OCUL) Sees Strong Trading Volume marketbeat.com - April 19 at 11:58 AM
	Ocular Therapeutix (NASDAQ:OCUL) Stock Rating Reaffirmed by HC Wainwright marketbeat.com - April 19 at 8:19 AM
	Ocular Therapeutix Shares Dive on Axpaxli Trial Results marketwatch.com - April 18 at 5:40 PM
	Ocular Therapeutix (NASDAQ:OCUL) Stock Price Down 9.2% marketbeat.com - April 18 at 12:59 PM
	Ocular Therapeutix Reports Positive Phase 1 Data For Axpaxli In NPDR markets.businessinsider.com - April 18 at 12:37 PM
	Ocular marks early-stage trial win for diabetic retinopathy candidate seekingalpha.com - April 18 at 7:37 AM
	Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy globenewswire.com - April 18 at 7:00 AM
	Age-related Vision Dysfunction Market Size in the 7MM is anticipated to increase by 2032, estimates DelveInsight theglobeandmail.com - April 17 at 9:08 PM
	Ocular Therapeutix appoints new CEO amid leadership shift uk.investing.com - April 17 at 4:02 PM
	Ocular Therapeutix (NASDAQ:OCUL) Shares Gap Up to $7.79 marketbeat.com - April 17 at 11:37 AM
	Analysts Offer Insights on Healthcare Companies: Walgreens Boots Alliance (WBA), Ocular Therapeutix (OCUL) and Elevance Health (ELV) markets.businessinsider.com - April 17 at 10:57 AM
	Ocular Therapeutix (NASDAQ:OCUL) Given Market Outperform Rating at JMP Securities americanbankingnews.com - April 17 at 4:14 AM
	The Analyst Verdict: Ocular Therapeutix In The Eyes Of 8 Experts markets.businessinsider.com - April 16 at 6:27 PM
	JMP Securities Reaffirms Market Outperform Rating for Ocular Therapeutix (NASDAQ:OCUL) marketbeat.com - April 16 at 11:21 AM
	Ocular Therapeutix(TM) Strengthens Clinical Team with Appointment of Key Retinal Leaders stockhouse.com - April 16 at 7:53 AM
	Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders finance.yahoo.com - April 16 at 7:53 AM
	Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Buy" from Analysts americanbankingnews.com - April 16 at 4:22 AM
	Short Interest in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Increases By 28.9% marketbeat.com - April 15 at 5:09 PM
	Biotech on a Budget: 7 Stocks Under $10 With Huge Potential investorplace.com - April 15 at 12:54 PM
	Ocular Therapeutix (NASDAQ:OCUL) Shares Gap Down to $7.99 marketbeat.com - April 15 at 12:53 PM
	Ocular Therapeutix CEO Mattessich Steps Down, Executive Chairman Fills Role marketwatch.com - April 15 at 10:54 AM
	Ocular Therapeutix CEO Mattessich To Step Down, Dugel To Succeed markets.businessinsider.com - April 15 at 10:54 AM
	Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO globenewswire.com - April 15 at 7:00 AM
	Remedies Recommended For Ocular Rosacea msn.com - April 13 at 3:24 PM
	Ocular Therapeutix (NASDAQ:OCUL) Shares Up 3.9% marketbeat.com - April 11 at 1:47 PM
	Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics globenewswire.com - April 9 at 7:30 AM
	Ocular Therapeutix (NASDAQ:OCUL) Shares Gap Up to $8.44 marketbeat.com - April 8 at 11:36 AM
	Buy Rating Affirmed: Paxtrava’s Promising Efficacy and Safety Profile in Glaucoma Treatment markets.businessinsider.com - April 8 at 2:39 AM
	Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting globenewswire.com - April 6 at 10:00 AM
	Ocular Therapeutix (NASDAQ:OCUL) Stock Rating Lowered by StockNews.com marketbeat.com - April 5 at 11:10 PM
	Ocular Therapeutix (NASDAQ:OCUL) Trading Up 5.3% marketbeat.com - April 4 at 2:03 PM
	Ocular Therapeutix (NASDAQ:OCUL) Trading Down 4% marketbeat.com - April 1 at 2:58 PM
	Million-Dollar Bets: 3 Under-$15 Stocks With Massive Potential investorplace.com - April 1 at 10:09 AM
	Deltec Asset Management LLC Grows Stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL) marketbeat.com - March 31 at 8:00 PM
	Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery) globenewswire.com - March 26 at 7:30 AM
	Legato Capital Management LLC Invests $667,000 in Ocular Therapeutix, Inc. (NASDAQ:OCUL) marketbeat.com - March 25 at 6:10 AM
	Q4 2023 Clearside Biomedical Inc Earnings Call finance.yahoo.com - March 21 at 2:00 AM
	Ocular Therapeutics' Impressive Surge: A Strategic Insight seekingalpha.com - March 19 at 4:04 PM
	Ocular Therapeutix (NASDAQ:OCUL) Stock Rating Upgraded by StockNews.com marketbeat.com - March 18 at 2:27 AM
	HC Wainwright Brokers Raise Earnings Estimates for Ocular Therapeutix, Inc. (NASDAQ:OCUL) marketbeat.com - March 18 at 1:28 AM
	OCUL Apr 2024 12.500 put finance.yahoo.com - March 17 at 8:32 AM
	Ocular Therapeutix (NASDAQ:OCUL) Shares Up 4.8% marketbeat.com - March 15 at 12:37 PM
	Buy Rating Affirmed for Ocular Therapeutix on Robust Revenue Growth and Clinical Trial Prospects markets.businessinsider.com - March 13 at 4:02 PM
	Ocular Therapeutix (NASDAQ:OCUL) Shares Gap Up to $9.29 marketbeat.com - March 13 at 12:33 PM
	Decoding 6 Analyst Evaluations For Ocular Therapeutix markets.businessinsider.com - March 13 at 10:18 AM
	Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Bought by GSA Capital Partners LLP marketbeat.com - March 13 at 5:32 AM
	Buy Rating Affirmed for Ocular Therapeutix on Strong Financials and Promising Pipeline Developments markets.businessinsider.com - March 12 at 1:07 PM
	These Analysts Boost Their Forecasts On Ocular Therapeutix After Q4 Results markets.businessinsider.com - March 12 at 1:07 PM
	Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Fourth Quarter and Full Year 2023 Results finanznachrichten.de - March 12 at 8:07 AM

Get Ocular Therapeutix News Delivered to You Automatically

Tiny Biotech Stock Wins $75 Billion Patent (Ad)

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

OCUL Media Mentions By Week

OCUL Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

OCUL
News Sentiment
▼
0.64

0.52
▲
Average
Medical
News Sentiment

OCUL News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

OCUL Articles
This Week
▼
27

3
▲
OCUL Articles
Average Week

Get Ocular Therapeutix News Delivered to You Automatically

Related Companies and Tools

Related Companies:

Headlines Tools:

This page (NASDAQ:OCUL) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Ocular Therapeutix (OCUL) News Today

OCUL Media Mentions By Week

OCUL Media Sentiment

OCUL News Coverage

Related Companies and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info